News
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.
-
Generative AI: Revolutionizing Pharmaceutical Industry and Driving Precision Medicine With Innovation, Equity and Ethics
With conscious and ethical use of Generative AI we can forge a future that is empathetic, innovative and can meet all our needs at the right time and place.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine
ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
-
BeiGene, Novartis Drug Alliance Ends; It’s Their Second Terminated Deal This Year
BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.
-
Breaking Through Gridlock in the Mental Health Care System
For the gridlock in mental healthcare to be resolved, 100% of mental healthcare providers must practice measurement-based care, utilizing validated rating scales to monitor and measure longitudinal outcomes for every patient. And payers then must offer reimbursement that appropriately rewards providers for delivering high-quality, effective care, and incentivize proactive mental health management.
-
3 Tech Investment Lessons From Houston Methodist’s Chief Innovation Officer
Roberta Schwartz, Houston Methodist’s chief innovation officer, has had years of experience overseeing technology adoption at her organization. At a conference, she highlighted how important it is for digital health tools to have strong EHR integrations and encouraged hospital leaders to not be afraid of starting various technology initiatives in unrelated areas.
-
Startup Magnet Biomedicine Attracts $50M to Expand Scope of Molecular Glue Drugs
Magnet Biomedicine builds on decades of molecular glue research from its scientific co-founder, Harvard University Professor Stuart Schreiber. The startup is developing drugs that take these glues beyond the biotech industry’s current focus on targeted protein degradation.
-
MedCity Influencers, Health Tech
How Femtech Is Filling Historical Gaps in the Postpartum Space
Postpartum Depression has been a recognized — but stigmatized — possibility during the so-called “fourth trimester of pregnancy” for generations. However, it is now being firmly addressed through femtech innovations.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
BioNTech and CEPI Team Up to Develop Mpox Vaccine That Meets 100-Day Goal
The Coalition for Epidemic Preparedness Innovations, or CEPI, has pledged up to $90 million to BioNTech’s messenger RNA vaccine candidates for mpox. This research could help advance the scientific understanding of the application of mRNA technology to Orthopoxviruses, which includes mpox, formerly known as monkeypox.
-
How HCA Is Integrating Google’s Generative AI Into Its Emergency Departments
This year, HCA Healthcare and Google Cloud have expanded their partnership by exploring ways to integrate Google’s generative AI into HCA’s workflows. The most developed project under this initiative is a pilot that began in February in which HCA’s emergency department physicians are testing a voice-enabled medical dictation tool to save them time on clinical documentation.
-
Data-Driven Diversity: Using Granular Insights to Design More Inclusive Trials
The healthcare industry is sitting on a wealth of data gathered from electronic health records, commercial pharmacies, health systems and payers, and health tech companies. So much that it makes up one-third of the world’s data. Pharmaceutical companies need to tap into this type of data to build inclusive clinical trials,
-
CardioOne Secures $8M, Expands Cardiology Enablement Platform into New Markets
CardioOne, a startup built at Redesign Health, partners with independent cardiology practices to help them transition to value-based care. On Monday, the company announced it has raised $8 million in seed funding and has three new partners.
-
Can AI Compose Clinical Documentation? Absolutely, but with Limits.
A recent academic study of the leading LLM AI models’ ability to read and interpret clinical information demonstrates the incredible power of these tools to support healthcare, but concludes that LLMs should be used as “a supplement to existing workflows rather than as a replacement for human expertise.”
-
How care orchestration technology improves the perioperative care process
It is no longer a question of whether we should use automation for care orchestration. The technology for intelligent automation of care coordination is available now and can help providers reduce costs, generate revenue, and overcome understaffing.
-
FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class
FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.
-
CMS Is Getting More Serious About Penalizing Hospitals For Price Transparency Noncompliance
CMS has fined two hospitals in September for alleged violations of its price transparency rule. This marks the third month in a row that the agency has issued fines against hospitals for price transparency noncompliance, following a yearslong period of light enforcement.
-
RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials
RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.